Cetuximab and irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) (AIO) is active and safe in the first-line treatment of metastatic colorectal cancer (mCRC) expressing the epidermal growth factor receptor (EGFR)

Research output: Contribution to journal › Meeting abstract › Contributed › peer-review

Contributors

  • G. Folprecht - , Department of internal Medicine I (Author)
  • M. P. Lutz - (Author)
  • P. Schoeffski - (Author)
  • T. Seufferlein - (Author)
  • A. Nolting - (Author)
  • P. Pollert - (Author)
  • C. Koehne - (Author)

Details

Original languageGerman
Pages (from-to)199-199
Number of pages1
JournalEuropean Journal of Cancer : EJC Supplements
Volume3
Issue number2
Publication statusPublished - Oct 2005
Peer-reviewedYes

External IDs

ORCID /0000-0002-9321-9911/work/142252037

Keywords

Sustainable Development Goals